HEDS Home Page

Welcome to the Health Economics and Decision Science Section of ScHARR

The Section

The purpose of HEDS is to promote excellence in health care resource allocation decisions. HEDS makes major contributions in areas that include the valuation of health, the analysis of health policy, welfare and equity, technology appraisal,evidence synthesis, econometrics and information sciences.

We also lead several national research collaborations, supervise PhD students, contribute to Masters programmes, deliver external training courses and provide input to national committees. Find out more about our activities in the most recent issue of our newsletter.

Latest publications

Nalmefene for reducing alcohol consumption with alcohol dependence: an evidence review group perspective of a NICE Single Technology Appraisal. Stevenson M, Pandor A, Stevens JW, Rawdin A, Rice P, Thompson J, Morgan MY. Pharmacoeconomics.  8th April 2015.

Treatment switching in oncology trials and the acceptability of adjustment methods. Latimer NR. Expert Review of Pharmacoeconomics Outcomes Research 1-4. 20th April 2015. 

Tramadol for premature ejaculation: a systematic review and meta-analysis. Martyn-St James M, Cooper K, Kaltenhthaler E. BMC Urology 15-6. January 2015.

Consultancy, Innovation & Knowledge Transfer

HEDS delivers a vibrant portfolio of consultancy-funded research to the pharmaceutical and medical devices sector and the NHS. It utilises our broad range of skills and is complemented by tailored training courses covering a full range of research methods, as well as policy issues such as pricing and reimbursement. If you want to discuss any opportunities, please contact the HEDS Director of Consultancy - Philip Carver

Latest project news

The Collaboration for Leadership in Applied Health Research and Care Yorkshire and Humber (CLAHRC YH), which is funded by the NIHR, starts its five year programme in January 2014. The Health Economics theme is led by John Brazier.

ScHARR-TAG has been allocated the following topic as part of the NICE Technolgy Appraisal Programme: TK cell therapy following haploidentical haematopoietic stem cell transplant for adults with acute leukaemia. ScHARR-TAG is led by Eva Kaltenthaler and Matt Stevenson.

Section Director

Professor Simon Dixon

Deputy Section Director

Dr Eva Kaltenthaler

HEDS blog

The best way to keep up with our work and our impact on policy is to read the HEDS Blog. With over 70,000 hits from over 110 different countries recent blog posts also feature on Twitter: